Biodelivery Sciences Shares Surged Nearly 52% in Premarket Trading

Tiger Newspress2022-02-14

BioDelivery Sciences shares surged nearly 52% in premarket trading.Collegium Pharmaceutical, Inc.(Nasdaq: COLL) and BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today announced a definitive agreement pursuant to which Collegium will acquire BDSI for $5.60 per share in cash.

BDSI has a portfolio of pain and neurology products that address serious and debilitating conditions. BDSI’s commercial growth driver, BELBUCA, is a meaningfully differentiated schedule III opioid product and is highly complementary to Collegium’s portfolio of pain products. Additional products in the BDSI portfolio include Symproic®, a contributor, and ELYXYB, a neurology product in its early launch phase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • rlgt
    2022-02-15
    rlgt
    K
  • saral
    2022-02-15
    saral
    Wow
  • Tamashii
    2022-02-14
    Tamashii
    Late!
  • BettyT
    2022-02-14
    BettyT
    An Awesome Monday for BDSI!
  • Mml
    2022-02-14
    Mml
    Hmm
  • Young Young
    2022-02-14
    Young Young
    Too late for opportunist 
Leave a comment
16